Interleukin 13 and inflammatory markers in human sepsis

Interleukin (IL) 13 is an anti‐inflammatory cytokine that reduces inflammatory cytokine production, and enhances monocyte survival and MHC class II and CD23 expression. The only report of IL‐13 in human sepsis noted no increase in IL‐13 concentration, in contrast to animal data. This study further examined the expression of IL‐13 in relation to human sepsis.

[1]  L. Moldawer,et al.  SEPSIS SYNDROMES: UNDERSTANDING THE ROLE OF INNATE AND ACQUIRED IMMUNITY , 2001, Shock.

[2]  J. Cavaillon,et al.  Pro- versus anti-inflammatory cytokines: myth or reality. , 2001, Cellular and molecular biology.

[3]  R. Strieter,et al.  Chemokine C10 Promotes Disease Resolution and Survival in an Experimental Model of Bacterial Sepsis , 2000, Infection and Immunity.

[4]  P. Giannoudis,et al.  Immediate IL-10 expression following major orthopaedic trauma: relationship to anti-inflammatory response and subsequent development of sepsis , 2000, Intensive Care Medicine.

[5]  R. Strieter,et al.  Expression and Contribution of Endogenous IL-13 in an Experimental Model of Sepsis1 , 2000, The Journal of Immunology.

[6]  K. Reinhart,et al.  Outcome Prediction by Traditional and New Markers of Inflammation in Patients with Sepsis , 1999, Clinical chemistry and laboratory medicine.

[7]  K. Tadokoro,et al.  Interleukin-13 is involved in functional maturation of human peripheral blood monocyte-derived dendritic cells. , 1999, Experimental hematology.

[8]  H. Young,et al.  IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-gamma. , 1999, Journal of immunology.

[9]  U. Losert,et al.  Gene transfer with IL‐4 and IL‐13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence , 1998, European journal of immunology.

[10]  P. Allavena,et al.  IL‐10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages , 1998, European journal of immunology.

[11]  A. Minty,et al.  Interleukin-13 effects on activated monocytes lead to novel cytokine secretion profiles intermediate between those induced by interleukin-10 and by interferon-gamma. , 1997, European cytokine network.

[12]  F. Nicoletti,et al.  Prevention of endotoxin‐induced lethality in neonatal mice by interleukin‐13 , 1997, European journal of immunology.

[13]  D. Cockayne,et al.  IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production. , 1997, Journal of immunology.

[14]  J. Dipiro.  Cytokine Networks with Infection: Mycobacterial Infections, Leishmaniasis, Human Immunodeficiency Virus Infection, and Sepsis , 1997, Pharmacotherapy.

[15]  J. Licinio,et al.  Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Rackow,et al.  Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. , 1996, The Journal of laboratory and clinical medicine.

[17]  J. Kellum,et al.  The immune system: relation to sepsis and multiple organ failure. , 1996, AACN clinical issues.

[18]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[19]  D. Fuchs,et al.  Interleukin-13 effectively down-regulates the monocyte inflammatory potential during traumatic stress. , 1995, Archives of surgery.

[20]  F. Mills,et al.  Activated mast cells produce interleukin 13 , 1995, The Journal of experimental medicine.

[21]  J. Singer,et al.  A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. , 1993, Chest.

[22]  R. de Waal Malefyt,et al.  Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. de Waal Malefyt,et al.  Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[25]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[26]  D Chlebna-Sokół,et al.  Proinflammatory cytokines (IL-6, IL-8), cytokine inhibitors (IL-6sR, sTNFRII) and anti-inflammatory cytokines (IL-10, IL-13) in the pathogenesis of sepsis in newborns and infants. , 2001, Archivum immunologiae et therapiae experimentalis.

[27]  L. Armstrong,et al.  Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. , 1998, American journal of respiratory cell and molecular biology.

[28]  Toshio Suzuki,et al.  Induction of major histocompatibility complex class II antigens on human colonic epithelium by interferon-gamma, tumor necrosis factor-alpha, and interleukin-2 , 1998, Journal of Gastroenterology.

[29]  T. van der Poll,et al.  Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. , 1997, The Journal of infectious diseases.

[30]  J. D. de Vries,et al.  Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. , 1994, Immunology today.

[31]  M. Kaghad,et al.  Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. , 1993, Nature.